Literature DB >> 19331217

Efficacy of concurrent chemoradiotherapy for T1 and T2 laryngeal squamous cell carcinoma regarding organ preservation.

Goshi Nishimura1, Mamoru Tsukuda, Yasukazu Mikami, Hideki Matsuda, Choichi Horiuchi, Takahide Taguchi, Masahiro Takahashi, Mariko Kawakami, Makiko Watanabe, Tatsuo Niho, Hiroaki Abo, Sayaka Yamomoto.   

Abstract

BACKGROUND: Although the survival rate of early-stage laryngeal squamous cell carcinoma (SCC) patients treated by radiotherapy (RT) is sufficient, the larynx preservation rate is unsatisfactory. To improve the larynx preservation rate, such patients have been treated by RT with chemotherapeutic agents. PATIENTS AND METHODS: RT with or without uracil-tegafur (UFT) was performed for T1 cases, and UFT and carboplatin for T2 cases.
RESULTS: In T1 cases, 30 patients received RT and 16 patients received concurrent chemoradiotherapy (CCRT). In T2 cases, 28 patients received RT and 45 patients received CCRT. There were no significant differences in the response and survival rates between the treatment methods both in T1 and T2 cases. The 5-year larynx preservation survival rate was improved significantly by CCRT in T2 cases (66.7% vs. 93.3%; p < 0.01).
CONCLUSION: CCRT for early-stage laryngeal SCC patients was efficacious to improve the larynx preservation survival rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331217

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer.

Authors:  M Hata; T Taguchi; I Koike; G Nishimura; M Takahashi; M Komatsu; D Sano; K Odagiri; Y Minagawa; T Inoue
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

2.  Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx.

Authors:  Danielle L Gainor; Emily Marchiano; Emily Bellile; Matthew E Spector; Jeremy M G Taylor; Gregory T Wolf; Norman D Hogikyan; Mark E Prince; Carol R Bradford; Avraham Eisbruch; Francis Worden; Andrew G Shuman
Journal:  Otolaryngol Head Neck Surg       Date:  2017-06-13       Impact factor: 3.497

3.  Outcomes after radiation therapy for T2N0/stage II glottic squamous cell carcinoma.

Authors:  Karine A Al Feghali; Bassem Y Youssef; Abdallah S R Mohamed; Lara Hilal; Blaine D Smith; Ibrahim Abu-Gheida; Georges Farha; G Brandon Gunn; Jack Phan; Jan Lewin; Apurva Thekdi; William H Morrison; Adam S Garden; Clifton David Fuller; David I Rosenthal
Journal:  Head Neck       Date:  2020-06-02       Impact factor: 3.147

4.  Definitive radiotherapy for early stage glottic cancer by 6 MV photons.

Authors:  Chi-Chung Tong; Kwok-Hung Au; Roger Kai-Cheong Ngan; Foon-Yiu Cheung; Sin-Ming Chow; Yiu-Tung Fu; Joseph Siu-Kei Au; Stephen Chun-Key Law
Journal:  Head Neck Oncol       Date:  2012-05-18

5.  Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer.

Authors:  Kensei Nakata; Koh-Ichi Sakata; Masanori Someya; Katsutoshi Miura; Junichi Hayashi; Masakazu Hori; Masaru Takagi; Tetsuo Himi; Atsushi Kondo; Masato Hareyama
Journal:  J Radiat Res       Date:  2013-01-04       Impact factor: 2.724

6.  The Second-Look Procedure for Transoral Videolaryngoscopic Surgery for T1 and T2 Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer Patients: Protocol for a Nonrandomized Clinical Trial.

Authors:  Goshi Nishimura; Daisuke Sano; Kenichiro Yabuki; Yasuhiro Arai; Yoshihiro Chiba; Teruhiko Tanabe; Nobuhiko Oridate
Journal:  JMIR Res Protoc       Date:  2017-12-05

7.  WRAP53β, survivin and p16INK4a expression as potential predictors of radiotherapy/chemoradiotherapy response in T2N0-T3N0 glottic laryngeal cancer.

Authors:  Katharina Tiefenböck-Hansson; Aaro Haapaniemi; Lovisa Farnebo; Björn Palmgren; Jussi Tarkkanen; Marianne Farnebo; Eva Munck-Wikland; Antti Mäkitie; Stina Garvin; Karin Roberg
Journal:  Oncol Rep       Date:  2017-08-11       Impact factor: 3.906

8.  Oxidative stress induced by carboplatin promotes apoptosis and inhibits migration of HN-3 cells.

Authors:  Pei-Jie He; Rui-Feng Ge; Wen-Jing Mao; Phil-Sang Chung; Jin-Chul Ahn; Hai-Tao Wu
Journal:  Oncol Lett       Date:  2018-10-10       Impact factor: 2.967

9.  A prospective clinical trial of the second-look procedure for transoral surgery in patients with T1 and T2 laryngeal, oropharyngeal, and hypopharyngeal cancer.

Authors:  Goshi Nishimura; Daisuke Sano; Yasuhiro Arai; Takashi Hatano; Hideaki Takahashi; Teruhiko Tanabe; Takashi Wada; Daiki Morishita; Nobuhiko Oridate
Journal:  Cancer Med       Date:  2019-10-08       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.